Hematological changes induced by various stress stimuli are accompanied by replacement of the primary acetylcholinesterase (AChE) 3 0 splice variant acetylcholinesterase-S (AChE-S) with the myelopoietic acetylcholinesterase-R (AChE-R) variant. To search for putative acetylcholinesterase-S interactions with hematopoietic pathways, we employed a yeast two-hybrid screen. The transcriptional co-repressor C-terminal binding protein (CtBP) was identified as a protein partner of the AChE-S C terminus. In erythroleukemic K562 cells, AChE-S displayed nuclear colocalization and physical interaction with CtBP. Furthermore, co-transfected AChE-S reduced the co-repressive effect of CtBP over the hematopoietic transcription factor, Ikaros. In transgenic mice, overexpressed human (h) AChE-S mRNA induced selective bone marrow upregulation of Ikaros while suppressing FOG, another transcriptional partner of CtBP. Transgenic bone marrow cells showed a correspondingly elevated potential for producing progenitor colonies, compared with controls, while peripheral blood showed increased erythrocyte counts as opposed to reduced platelets, granulocytes and T lymphocytes. AChE's 3 0 alternative splicing, and the corresponding changes in AChE-S/CtBP interactions, thus emerge as being actively involved in controlling hematopoiesis and the potential for modulating immune functions, supporting reports on malfunctioning immune reactions under impaired splice site selection.
Introduction
Mammalian hematopoiesis involves cell proliferation, lineage selection and maturation events, some of which include excision-splicing choices that change the mRNA products of multiple pre-mRNAs in blood cell progenitors. [1] [2] [3] [4] This enables the complexity needed to maintain hematopoiesis and react rapidly to altered conditions. The consequent modifications in the alternative splicing profile determine the binding properties, intracellular localization, biochemical activities and stability of many proteins. 5, 6 An example of a hematopoietically active gene that is subject to alternative splicing in reaction to external stimuli is that of acetylcholinesterase (AChE), the enzyme responsible for acetylcholine hydrolysis. The principal AChE mRNA transcript joins exon (E) 4 to E6 to give rise to acetylcholinesterase-S (AChE-S), the 'synaptic' isoform, with an amphipathic C terminus of a-helical structure. 7 Another transcript, acetylcholinesterase-R (AChE-R), expressed in embryonic and tumor cells, 8 is formed by continuous transcription through intron I4. Multiple stress stimuli involve increased ratio between AChE-R and AChE-S in brain and blood cells alike. 9, 10 AChE-R interacts with the intracellular scaffold protein RACK1 and its protein kinase C (PKC) partner through its C-terminal peptide, ARP. 11 In hematopoietic cells, this induces myelopoiesis. 9 Also, transgenic mice overexpressing AChE-R display elevated lymphopoiesis and platelet counts. 12, 13 Nevertheless, it remained unclear whether the gain of AChE-R function by itself suffices to induce the myelopoiesis and thrombocytosis that follow stress insults, or if the loss of AChE-S function(s) is also causally involved.
In cultured promegakaryocytes, AChE localizes to the nucleus, and is suppressed during megakaryocytopoiesis. 14 Furthermore, ACHE gene expression was reported to increase in various cell types during apoptosis, 15 and silencing the ACHE gene by small interference (si)RNA prevented the propagation of apoptosis. 16 To search for the specific AChE variant(s) involved in these phenomena, we employed ASP 67 , a highly evolutionarily conserved peptide, derived from the human AChE-S C terminus (www.esterneuro.com), as bait for a yeast twohybrid screen. To identify effects on normal hematopoiesis of the splice site selection process determining the AChE-S/AChE-R ratio, we used TgS transgenic mice overexpressing the nuclearly localized AChE-S variant. We identified the pivotal co-repressor C-terminal binding protein (CtBP) as an AChE-S partner, an interaction that affects the CtBP co-repressive effect over the hematopoietic transcription factor Ikaros. The TgS bone marrow was correspondingly found to express high levels of Ikaros, as compared to controls, and their peripheral blood presented a relative erythrocytosis, thrombocytopenia and T-cell lymphopenia. These observations demonstrate that AChE-S serves as a multi-lineage hematological effector that regulates, through CtBP, the transcriptional activities of several hematopoietic transcription factors.
Materials and methods

Animals
Transgenic (TgS) mice carry the human 'synaptic' AChE-S coding sequence and the proximal 586 bp of the human AChE promoter in an FVB/N background. 17 Peripheral blood, drawn from the retroorbital vein of 3-month-old female TgS mice and gender-matched control FVB/N mice, was collected in ethylene-diaminetetraacetic acid (EDTA) (7.5%) tubes. Marrow cells were harvested as detailed. 13 In situ hybridization and intracellular localization of AChE-S mRNA were performed as detailed. 9, 18 AChE catalytic activity was determined as detailed.
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Cell cultures K562 and human embryonic kidney (HEK) 293 cells were grown in RPMI and Dulbecco's modified Eagle's medium (DMEM, Biological Industries, Beit Ha'emek, Israel; Sigma, Jerusalem, Israel), both supplemented with 10% fetal calf serum (FCS) and 2 mM L-glutamine (Biological Industries) at 371C, in a humidified chamber with 5% CO 2 .
Progenitor colony assays
TgS and FVB/N BM cells were cultured at 2 Â 10 5 cells per 35 mm tissue culture dish (Corning Inc., Corning, NY, USA). CFU-GEMM, CFU-GM and CFU-Mk were grown as previously described. 13 BFU-E were cultured in Alpha-MEM (Biological Industries) supplemented with 0.8% methyl cellulose, 10% FCS, 10% bovine serum albumin (BSA, Boehringer Ingelheim GmbH, Biberach an der Riss, Germany) 2-mercaptoethanol, 3 U/ml recombinant human (r-hu)-erythropoietin and 10 ng/ml r-mouse-CSF.
Flow cytometric acquisition and analysis
A total of 2 Â 10 6 cells (50 ml) were incubated (30 min, 41C) with the required antibody dilutions, washed with 5 ml 1% BSA in PBS and centrifuged (600 g, 5 min, 41C). Red blood cells (RBCs) were lysed with 1 ml of 1:10 diluted FACS lysis buffer (BD Bioscience, Erembodegem, Belgium; 12 min, 41C). Six-parameter, four-color flow cytometry involved collection with a BD FACS Calibur (BD Biosciences, Palo Alto, CA, USA) of at least 50 000 events per sample. Fluorescent detectors sensitivity, adjustment, isotype controls and analysis were all as detailed. 9, 13 Antibodies used for flow cytometry are listed in Supplementary information.
Two-hybrid screening
Yeast AH109 cells (Clontech Laboratories, Palo Alto, CA, USA) were transformed with the pGBK-ASP67 plasmid (Yeastmaker transformation system, Clontech), including the DNA-binding domain (DBD; residues 1-147) of the yeast GAL4 transcriptional activator, then with 10-25 mg of an amplified human fetal brain cDNA library. Screening covered 240 000 independent clones in the GAL4 activation domain vector. 11 The 'bait' plasmid pGBK-ASP67 included an EcoRI/HpaI fragment of human AChE-S cDNA (nucleotides 1794-2001 of hACHE, accession no. M55040), cloned into the EcoR1/SmaI sites of pGBK-T7 (Clontech). Screening was as described.
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Vectors AChE-S under cytomegalovirus (CMV) control and fusion proteins of GFP and AChE C-terminal peptides were as described. 10, 18 For luciferase assays, we used the pcDNA3.Gal4 DBD (activating the reporter gene), pcDNA3.mCtBP2 (encoding murine CtBP2) and pcDNA3.Gal4DBD.Ikaros1-81, encoding Gal4 DBD fused to the CtBP-interacting region of Ikaros (Ik1-81), 19, 20 all a kind gift from Dr M Crossley (Sydney, Australia). The firefly luciferase reporter vector, pGL2(Gal4) 5 TK, contained five copies of the Gal4 DBD upstream of the TK promoter in the vector pGL2-TK (Promega, Madison, WI, USA).
Transfections
K562 or HEK 293 cells seeded in 25 cm
2 flasks were transfected with a mixture of Lipofectamine 2000 reagent (Gibco BRL Life Technologies, Bethesda, MD, USA), 12 mg of either AChE-S, CtBP, pGASP or the control pEGFP-C2 plasmid (Clontech Laboratories), or combinations thereof, using DMRIE-C reagents (Gibco) as instructed.
Reporter gene assays
HEK 293 cells seeded in six-well plates were transfected with Lipofectamine 2000 reagent (Gibco) and 0.2 mg of Renilla pRL-SV40 plasmid (Promega), as internal control, 1 mg of pGL2(Gal4) 5 TK, or various combinations of 1 mg of pcDNA3. Gal4DBD, 1 mg of pcDNA3.mCtBP2, 1-0.1 mg of pcDNA3. Gal4DBD.Ikaros1-81 and 1 mg of AChE-S plasmids. Transfected DNA (4 mg) amounts were kept constant by addition of 'naked' pcDNA3 vector. Luciferase activity was measured in triplicate, 24 h post-transfections. The dual luciferase system and a single tube luminometer (Lumac/3M, Biocounter M2010A) were used as instructed (Promega).
Co-immunoprecipitation
K562 cells were centrifuged (10 min) at 1500 r.p.m., resuspended and lysed as described. 21 HEK 293 cell homogenates were prepared as in Birikh et al. 11 Protein extracts were incubated (overnight, 41C) with 2 mg rabbit anti-human CtBP polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), then with 50 ml of suspended 4 Fast Flow protein A Sepharose beads (GE Healthcare Ltd., Little Chalfont, UK; 1 h, 41C). Sedimented beads were washed three times in NET buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.25% gelatin and complete mini protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany)), suspended in sample buffer, heated (951C, 5 min) and centrifuged at maximal speed to remove beads.
Immunoblot
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA, USA) involved blotting onto nitrocellulose membranes, incubation in a blocking solution (3% skim milk, 2% BSA, 0.3% Tween 20 in Trisbuffered saline, 1 h, room temperature), immunolabeling (41C, overnight) with goat anti-human AChE N terminus (Santa Cruz Biotechnology, diluted 1:500), development (room temperature, 2 h) with horseradish peroxidase-conjugated goat anti-rabbit or donkey anti-goat antibodies diluted 1:10 000 (Jackson ImunoResearch laboratories Inc., West Grove, PN, USA) and chemiluminescence (ECL) kit (Amersham) detection.
Real time RT-PCR
Bone marrow RNA purified with the RNeasy kit (Qiagen, Hilden, Germany) was treated with DNase I (Qiagen) as instructed, electrophoresed on an agarose gel, used for cDNA preparation (Improm II, (Promega)) as instructed, incubated for 45 min at 421C, 15 min at 721C, 5 min at 901C and stored at 41C.
Quantitative RT-PCR tests involved the Lightcycler (Roche, Applied Science, Mannheim, Germany) and SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA).
Transcript amplification at the log linear range reached similar efficiencies (amplification of Bn 1.8 per PCR cycle) for all targets. Amplification reactions (10 ml) contained 1 ml of five-fold diluted RT reaction product, 1 ml SYBR Green PCR Master Mix, 10 mM primer (Table 1) and nuclease-free water.
cDNA quantities were normalized against housekeeping b-actin, based on the value DTar ¼ Tar t Àb-actin t (the difference in cycles no. for reaching threshold between the tested target and b-actin). The distributions of the DTar values were compared for the FVB/N and TgS mice, using a non-parametric Kruskal-Wallis test (MATLAB statistical toolbox). P-values below 0.05 were considered significant.
Results and discussion
The 3
0 splice variants of AChE all share a single common domain yet differ in their C-terminal peptides ( Figure 1a ). Under stress, AChE-S is substituted with AChE-R. 10 Consequent myelopoiesis could be solely due to AChE-R's capacity to upregulate hematopoiesis. 9 Alternatively, the decrease in AChE-S could also be actively involved, by avoiding negative regulatory function(s). To distinguish between these hypotheses, we used ASP 67 , the AChE-S C-terminal domain, as bait for a yeast two-hybrid screen.
ASP, the AChE-S C-terminal peptide, interacts with the co-repressor CtBP ASP 67 served as bait for the Gal 4 two-hybrid system. Several potential partner proteins enabled survival of 64 yeast colonies expressing the ASP 67 AChE-S peptide in a screening of 240 000 independent clones from a human brain-originated cDNA library, with 16 showing homology to nuclearly localized proteins or ESTs, suggesting regulatory functions. One of these clones included a 485 bp insert with 98% homology to part of the human C-terminal binding protein 2 (hCtBP2) (accession no. NM_001329.1) (Figure 1 ), a ubiquitous corepressor that facilitates gene regulation during development and oncogenesis. 22 ASP 67 /CtBP-expressing yeast colonies displayed intensive b-galactosidase activity. No interaction with CtBP was detected in library screens with the AChE-R C-terminal peptide, ARP 51 , suggesting splice variant specificity of the ASP 67 /CtBP interaction.
Nuclear localization and CtBP co-immunoprecipitation of AChE-S in HEK 293 and K562 cells
In cultured rat pheochromocytoma PC12 cells, ASP 67 accumulates in the nucleus. 18 To study the relevance of this targeting to Table 1 Primer sequences used for real time PCR
Primer Sequence
Abbreviation: CtBP2, C-terminal binding protein 2.
Figure 1 ASP67, the C-terminal domain of AChE-S, interacts with CtBP. (a) The ACHE gene produces, through 3 0 alternative splicing, two major mRNA products: AChE-S and AChE-R. Under stress, an S-to-R shift suppresses the levels of the nuclearly targeted AChE-S protein and its ASP C terminus. 10 (b) The CtBP 2 amino-acid sequence. The ASP 67 -binding domain is highlighted. The amino-acid sequence translated from sequence in two-hybrid clone is shown below. AChE, acetylcholinesterase; AChE-S, acetylcholinesterase-S; AChE-R, acetylcholinesterase-R; CtBP 2 , C-terminal binding protein 2.
Acetylcholinesterase partners in hematopoiesis C Perry et al hematopoiesis, we searched for ASP 67 localization in the K562 human erythroleukemia cells. Transfection with GFP fusion proteins carrying the C-terminal peptides of human AChE-S (GASP) and AChE-R (GARP) (Figure 2a ) revealed that GASP primarily accentuated fluorescence within K562 nuclei whereas GARP promoted cytoplasmatic labeling, similar to COS and PC12 cells (Figure 2b ). 18 AChE-S colocalization with nuclear protein(s) (for example CtBP) in hematopoietic cells suggested physiological relevance for this interaction.
To establish the biological relevance of the ASP 67 /CtBP interaction, observed in the yeast two-hybrid screen, we employed co-immunoprecipitation. AChE-S, but not AChE-R, was co-immunoprecipitated together with CtBP from extracts of HEK 293 cells co-transfected with CtBP and AChE-S (Figure 2c and data not shown), demonstrating variant specificity of the AChE-S/CtBP interaction. In erythroleukemia, K562 cell homogenates overexpressing human AChE-S, anti-CtBP antibodies coimmunoprecipitated AChE together with endogenous CtBP (Figure 2d) , demonstrating that the ASP 67 /CtBP interaction can occur with the intact AChE protein in hematopoietic cells.
CtBP/AChE-S interaction involves the NAD þ binding domain of CtBP
CtBP proteins are evolutionarily-conserved, non-DNA binding co-repressor phosphoproteins, interacting with sequencespecific DNA binding transcriptional repressors. 23 In mammals, FOG, TCF4, BKLF, Ikaros and Smad 6 are among the transcription repressors mediating their CtBP interaction effects through consensus PXDLS motif. 23, 24 CtBP possesses an NAD þ -dependent dehydrogenase activity and undergoes NADH-dependent conformational changes. The hCtBP2 sequence domain, which conferred binding to ASP 67 in the two-hybrid system (residue nos. 169-332), spans the central region of CtBP and residues R266, D290, E295 and H315. This region is involved in binding of PXDLS-containing proteins but lacks the major PXDLSbinding region that spans residues 1-199 25, 26 (Figure 3a) . A considerable identity (86%) with the CtBP NAD þ -binding domain (hCtBP1 (accession no. Q13363), hCtBP2 (accession no. P56545) and rat CtBP3 (Q9Z2F5), Figure 1b ) was found by Blast (www.ncbi.nih.gov.entrez) followed by ClustalW analysis (www.ebi.ac.uk/clustalw) of the 225 aa encoded by the ASP 67 -bound sequence.
The ASP sequence lacks the PXDLS consensus motif, similar to several other CtBP-binding proteins (e.g. histone-modifying enzymes HDAC1,2), 27 which likely bind CtBP through structural components. When modeled, HDAC1 emerged as including surface-exposed helices, and masked beta-sheets. Together, this suggested that AChE-S may interact with CtBP through its ASP helical domain. We generated a model of the ASP 67 -binding CtBP region of 174 aa using the SWISS-MODEL software, 28 based on the two solved structures of CtBP homologues (1HKU and 1MX3) as templates (Figure 3b) . Importantly, the modeled ASP 67 was found to fit a trough on the surface of the modeled CtBP 2 protein (Figure 3b) , that spans part of the residues involved in CtBP binding of PXDLS-containing proteins (residues R266, D290, E295 and 67 and GARP 51 vectors, encoding fusion proteins of GFP with C-terminally fused ASP 67 (the AChE-S C terminus, which served for the two-hybrid screen) and ARP 51 (which failed to interact with CtBP in a parallel screen). Note the a-helical structure of the GASP peptide (following Dvir et al.
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) and the null structure of ARP 51 , which emerges as naturally unfolded. ). This suggested effects of CtBP/AChE-S interactions on both CtBP's protein interactions and its conformational changes.
AChE-S interferes with the CtBP co-repressive effects over Ikaros
To challenge the physiological relevance of the nuclear AChE-S/ CtBP interaction, we tested if coexpressed AChE-S affects CtBP's capacity to interact with its known partner, the hematopoietic transcriptional repressor, Ikaros, and corepresses gene expression (Figure 4a ). Repression of transcription by Ikaros in mammalian cells was verified using a GAL4DBD-IK1-81 fusion protein carrying the CtBP-binding domain of Ikaros. 20 A luciferase reporter gene served to quantify the repressor activity (Figure 4b ). CtBP, alone or co-transfected with AChE-S, suppressed luciferase gene expression in HEK 293 cells by 40-fold. The GAL4DBD-IK1-81 (Ik) fusion protein repressed luciferase activity by 50-fold, and was refractory to co-transfection with AChE-S. CtBP together with Ik showed a potentiated suppression of 67-fold of luciferase activity (P ¼ 0.01; P ¼ 0.002 as compared to Ik alone, ANOVA). Intriguingly, triple transfection with CtBP, Ik and AChE-S expression vectors reduced the suppression capacity back to 40-fold (Po0.001 as compared to cells with non-suppressed luciferase activity or cells co-transfected with CtBP and Ik, ANOVA) (Figure 4c ). These findings suggested that the AChE-S/ CtBP interaction interferes with the CtBP co-repressive effect over Ikaros activity.
CtBP was reported to exert anti-apoptotic effects, 29 whereas AChE was reported to play a central role in the induction of apoptosis. 15, 16 A CtBP/AChE-S interaction that competes with and impairs the formation of other CtBP complexes can interfere with CtBP's anti-apoptotic activities. This may lay a molecular basis for the mechanism by which nuclear AChE-S induces a pro-apoptotic effect, alternatively or additionally to its APAF complex formation. 16 Supporting this notion, present work shows AChE-S-induced apoptosis in primary lymphocytes from TgS mice (Gilboa-Geffen et al., 12 in preparation).
AChE-S excess increases the growth potential of bone marrow progenitors
Transgenic TgS mice expressing a human promoter-reporter AChE-S construct (Figure 5a ) show hematopoietic expression of this transgene. In bone marrow smears from TgS and strainmatched FVB/N mice serving as controls, a specific 2 0 -Omethylated cRNA selective for human AChE-S mRNA (less than 40% homology with the corresponding mouse sequence) showed specific staining in bone marrow cells from TgS mice but not FVB/N controls (Figure 5b) . Nevertheless, bone marrow cell extracts from TgS and FVB/N mice showed similar AChE activities, probably due to the relatively low expression potency of the proximal ACHE promoter. 30 The ability of primary bone marrow cells from TgS and FVB/N mice to give rise to either the multipotential CFU-GEMM, erythroid BFU-E, megakaryocytic CFU-MK or granulocyte/ monocyte CFU-GM colonies was tested (Figure 6a ).
Significant increases were observed in the number of CFU-GM, BFU-E and CFU-MK, but not the multi-potential CFU-GEMM from cultured TgS as compared to FVB/N bone marrow cells (Figure 6b ). This suggested that AChE-S exerts no effects on multi-potential cells but operates on hematopoietic cells that are already partially committed. Also, the inherently increased growth potential of TgS progenitors was apparently suppressed in vivo, likely by feedback mechanisms, involving local modifications by stromal cells that are avoided in in vitro cultures. 31 TgS bone marrow cell populations were subclassified by specific antibody markers aimed at stem cells (CD34, Sca1), myeloid and monocytic cells (Gr1, CD11b), lymphocytes (CD19, CD3, CD4, CD8), megakaryocytes (CD41) and erythroid cells (CD71, Ter119). Immunophenotyping by flow cytometry revealed no significant differences between FVB/N and TgS mice in any of the hematopoietic lineages.
TgS mice present an unusual peripheral blood phenotype
In the peripheral blood, similar to the bone marrow, AChE hydrolytic activities were comparable in FVB/N and TgS mice (data not shown). However, peripheral blood cell counts of all three cell lineages diverged in TgS mice from those of strainmatched FVB/N counterparts ( Table 2) . TgS hemoglobin (Hgb) levels were slightly but significantly elevated, as were total RBC counts, suggesting physiologically relevant changes, although within normal range. Conversely, platelet (Plt) counts were significantly decreased in TgS as compared to FVB/N mice, again remaining within normal range, perhaps suggesting that the corresponding joint progenitors (CFU-GEMM) tend towards erythropoiesis over the choice of megakaryocytopoiesis. Mean white blood cell (WBC) counts were significantly reduced as compared to the leukocyte counts in FVB/N mice (476071760 and 642071620 Â 10 3 /ml, respectively, t-test Po0.004). Importantly, immunophenotyping of WBC sub-populations by flow cytometry revealed specific decreases in TgS GR1 þ myeloid cells and T lymphocytes (both T helper (CD4 þ ) and T suppressor cells (CD8 þ )), but not in monocytes (CD11b þ ) or B lymphocytes (CD19 þ ) (Figure 7a ). This unusual blood cell profile was opposite to the stress-induced enhancement of granulopoiesis and thrombocytosis, under AChE-R overexpression. 12 We conclude that AChE-S excess, likely through alleviating the suppressive effects of CtBP with which it interacts, suppresses T lymphopoiesis and thrombopoiesis, in contrast to AChE-R, which promotes granulopoiesis and thrombopoiesis 9, 13 ( Figure 7b ).
Modified expression of transcription factors in TgS mice
To test if AChE-S exerts transcriptional modifications through interacting with factors such as CtBP, we quantified the expression levels of key hematopoietic transcription factors and regulators in bone marrow extracts from TgS and FVB/N controls ( Figure 7c and data not shown). The expression levels of CtBP, GATA1, LMO2, STAT5b, PU.1 and RUNX1/AML1 and the thrombopoietin receptor c-mpl were all comparable in FVB/N and TgS mice. However, the cDNA levels of the GATA1-binding transcription factor FOG were significantly lower (by 1.3 log) in TgS, but not in TgR, mice overexpressing AChE-R in bone marrow and blood, as compared to FVB/N controls (Figure 7c ). In contrast, Ikaros cDNA levels were over five-fold higher (by 2.7 log (based on a calculated increase of 1.8 log per cycle)) than controls. Both Ikaros and FOG transcriptional repression is known to be CtBP-mediated. 26, 32 Together, these findings suggested that ASP-specific effects alter the levels of FOG and Ikaros, representing reactive changes to the impaired in vivo transcriptional repression capacity of CtBP due to CtBP/AChE-S interactions.
Our data suggest that the long-lasting effects of AChE-S overexpression and impaired CtBP function inflicted compensatory feedback mechanisms that indirectly resulted in altered expression of FOG and Ikaros, in an attempt to maintain homeostasis. The mechanism(s) by which Ikaros and FOG expression were attenuated remain to be elucidated. It is not yet clear if the inverse type changes observed in these transcription factors (namely, an increase in Ikaros, a decrease in FOG) are due to the different modes of CtBP effects on them. Nevertheless, together they yield an increased CFU-GM clonogenicity in the TgS bone marrow, similar to what was previously shown for Ikaros null mice. 33 This suggests that impaired Ikaros transcriptional activities due to a CtBP/AChE-S interaction may result in both a compensatory increase in Ikaros mRNA levels and potentiated myelopoietic clonogenicity. The increase in Ikaros expression in TgS mice was likely insufficient for regaining full Ikaros function over genes where it requires CtBP cooperation. This is compatible with the reduced peripheral blood granulocyte levels of TgS mice and with parallel findings in Ikaros null mice. 33 In addition, reduced expression of FOG may enhance GATA-1-induced BFU-E proliferation (by relieving FOG's repression over GATA-1-induced activity 32 ). Together, our findings demonstrate that mal-adaptive splicing of AChE pre-mRNA can modify blood cells composition owing to multi-leveled modifications in multiple transcription regulators.
Conclusion
AChE has long been suspected to play a role in normal and tumorgenic hematopoieis. [34] [35] [36] In this study, we discovered a molecular mechanism underlying both the gain and loss of function consequences of AChE's splice site selection on normal hematopoiesis.
We found that the C-terminal peptide unique to human AChE-S interacts with and ameliorates the transcriptional co-repression capacities of CtBP, leading to changes in gene expression and in the composition of peripheral blood cells in a manner opposite to that induced by the normally rare variant AChE-R. As AChE-S is by far the major AChE splice variant in blood cells, 13, 37 our findings present AChE-S as a pivotal regulator of hematopoiesis, affecting cell fate decisions downstream to the GEMM progenitor cells. Under acute stress, 9,13 splice site selection would tilt the AChE-S/AChE-R balance, increasing AChE-R levels while decreasing AChE-S levels. Our current findings demonstrate that this can relieve the CtBP-mediated loss of function effects (by reducing AChE-S), in addition to the myelopoietic and thrombopoietic gain of function (by increasing AChE-R), reflecting a bimodal mode of regulation. The dual effects of AChE-S and AChE-R. ASP, the helical C terminus of AChE-S, interacts with CtBP, alleviating its co-repressive effects over hematopoietic transcription and inducing complex feedback reactions leading to T lymphopenia. ARP, the naturally unfolded C terminus of AChE-R, inversely promotes signaling and myelopoiesis through its interaction with RACK1 and PKCe. 13, 39 ) (c) Quantitative real-time PCR. Comparison of the noted transcript levels with the housekeeping gene b-actin mRNA showed significant (Po0.001, Kruskal-Wallis test) decreases in FOG mRNA and increases in Ikaros mRNA in the bone marrow of TgS but not FVB/N or TgR mice expressing the AChE-R transgene. 9 AChE, acetylcholinesterase; AChE-S, acetylcholinesterase-S; AChE-R, acetylcholinesterase-R; CtBP, C-terminal binding protein; PKCe, protein kinase C-e.
